Abstract
N-acetylcysteine (NAC), the N-acetyl derivative of the amino acid cysteine, is perhaps best known for its wide use in the treatment of acetaminophen (paracetamol) toxicity, but it has been investigated for the treatment of myriad conditions. In this article we will review the uses of NAC in pulmonary diseases, the mechanism of action dosing, side effect profile and clinical implications in regard to COPD and idiopathic pulmonary fibrosis. One of the main targets of NAC is Inflammation and oxidative stress that are important factors in the pathogenesis of many chronic inflammatory lung disorders. While it is logical to conclude that the administration of antioxidants such as NAC will provide a mode of treatment for said conditions by targeting antioxidant-oxidant imbalance [8] and although the theory supporting the use of antioxidants is sound, it may not necessarily translate into clinical benefit. Based on the available evidence it is unlikely that mucolytics such as NAC will drastically affect symptoms, exacerbations or disease modification in COPD.
Keywords: Interstitial lung diseases, N-Acetylcysteine, pulmonary diseases, side effects.
Current Respiratory Medicine Reviews
Title:The Use of N-Acetylcysteine in Respiratory Diseases
Volume: 9 Issue: 5
Author(s): Shoshannah Levitt, Daniel Grupel, Maor Waldman, Tamir Tobias and Theodore K. Marras
Affiliation:
Keywords: Interstitial lung diseases, N-Acetylcysteine, pulmonary diseases, side effects.
Abstract: N-acetylcysteine (NAC), the N-acetyl derivative of the amino acid cysteine, is perhaps best known for its wide use in the treatment of acetaminophen (paracetamol) toxicity, but it has been investigated for the treatment of myriad conditions. In this article we will review the uses of NAC in pulmonary diseases, the mechanism of action dosing, side effect profile and clinical implications in regard to COPD and idiopathic pulmonary fibrosis. One of the main targets of NAC is Inflammation and oxidative stress that are important factors in the pathogenesis of many chronic inflammatory lung disorders. While it is logical to conclude that the administration of antioxidants such as NAC will provide a mode of treatment for said conditions by targeting antioxidant-oxidant imbalance [8] and although the theory supporting the use of antioxidants is sound, it may not necessarily translate into clinical benefit. Based on the available evidence it is unlikely that mucolytics such as NAC will drastically affect symptoms, exacerbations or disease modification in COPD.
Export Options
About this article
Cite this article as:
Levitt Shoshannah, Grupel Daniel, Waldman Maor, Tobias Tamir and Marras K. Theodore, The Use of N-Acetylcysteine in Respiratory Diseases, Current Respiratory Medicine Reviews 2013; 9 (5) . https://dx.doi.org/10.2174/1573398X10666140204230324
DOI https://dx.doi.org/10.2174/1573398X10666140204230324 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Exposure to PM2.5 components is associated with respiratory diseases
Through continuous research on the relationship between risk factors and health, it has been found that air pollution, especially atmospheric particulate matter pollution, has become one of the main sources of global disease burden. From 1990 to 2022, the concentration of atmospheric particulate matter pollution has increased by more than ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Aspirin Intolerance: Experimental Models for Bed-to-Bench
Current Drug Targets Immunotherapy in Allergies: An Update
Inflammation & Allergy - Drug Targets (Discontinued) Imiquimod 5% Cream Use in Dermatology, Side Effects and Recent Patents
Recent Patents on Inflammation & Allergy Drug Discovery Clopidogrel Desensitization: Background and Recommendations for Use of a Rapid (4 Hour) Protocol
Current Vascular Pharmacology Neuro-AIDS: Current Status and Challenges to Antiretroviral Drug Therapy (ART) for Its Treatment
Current Drug Therapy Novel Drug-Induced Pulmonary Complications in Cancer Patients You Can Save Life!
Current Respiratory Medicine Reviews Biologic Agents in the Treatment of Psoriasis
Recent Patents on Inflammation & Allergy Drug Discovery Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery New Antihypertensive Drugs Under Development
Current Medicinal Chemistry Target Product Selection - Where Can Molecular Pharming Make the Difference?
Current Pharmaceutical Design Serine Proteinase Inhibitors in the Skin: Role in Homeostasis and Disease
Current Protein & Peptide Science Adverse Effects and Drug Interactions of Biologic Agents
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Current Strategies to Achieve Further Cardiac and Renal Protection through Enhanced Renin-Angiotensin-Aldosterone System Inhibition
Reviews on Recent Clinical Trials Downregulation of Membrane-bound Angiotensin Converting Enzyme 2 (ACE2) Receptor has a Pivotal Role in COVID-19 Immunopathology
Current Drug Targets Renin-Angiotensin System in Diabetes
Protein & Peptide Letters New Applications for Sublingual Immunotherapy in Allergy
Recent Patents on Inflammation & Allergy Drug Discovery Natural Proteinaceous Inhibitors of Serine Proteases
Current Pharmaceutical Design Angiotensin Converting Enzyme (ACE) Inhibitory Peptides: Production and Implementation of Functional Food
Current Pharmaceutical Design Complications Associated with Recombinant Tissue Plasminogen Activator Therapy for Acute Ischaemic Stroke
CNS & Neurological Disorders - Drug Targets Gene Patents in the Primary Prevention of Vascular Diseases
Recent Patents on DNA & Gene Sequences